Risk of cardiovascular disease in HIV-infected patients.

The life expectancy of people living with HIV infection has improved dramatically since the use of highly active antiretroviral therapy (HAART). Now that patients with HIV infection are living longer, the focus of its treatment should shift to long-term management spanning decades. Diseases of ageing, including cardiovascular disease (CVD), have now become more important. The evidence of cardiovascular risk associated with HIV infection and antiretroviral therapy is explored and discussed in this article.
AuthorsSatyajit Das
JournalThe Journal of antimicrobial chemotherapy (J Antimicrob Chemother) Vol. 65 Issue 3 Pg. 386-9 (Mar 2010) ISSN: 1460-2091 [Electronic] England
PMID20026610 (Publication Type: Journal Article)
Chemical References
  • Anti-HIV Agents
  • Anti-HIV Agents (therapeutic use)
  • Antiretroviral Therapy, Highly Active
  • Cardiovascular Diseases (epidemiology)
  • HIV Infections (complications, drug therapy)
  • Humans
  • Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: